title: Fasting serum growth hormone and insulin-like growth factor-I and -II concentrations in women with leiomyomata uteri treated with leuprolide acetate or placebo.
abstract: Eighteen patients with leiomyomata uteri were randomized to receive either leuprolide acetate depot (n = 9) 3.75 mg intramuscularly (IM) or placebo (n = 9) IM every 4 weeks for four injections. Leuprolide acetate treated patients demonstrated a reduction in mean uterine volume of 34% and a decrease in serum estradiol (E2) concentrations from 120 +/- 21 pg/mL (mean +/- standard error) to 16 +/- 9 pg/mL. Leuprolide acetate treated patients also demonstrated significant decreases in serum growth hormone (GH) (3.0 +/- 0.4 ng/mL versus 1.4 +/- 0.4 ng/mL) and insulin-like growth factor-I (IGF-I) concentrations (3.3 +/- 0.4 U/mL versus 1.3 +/- 0.2 U/mL) over the 12 week treatment period. Serum IGF-II levels did not change. Mean uterine volume and serum E2, GH, IGF-I, and IGF-II concentrations did not change in placebo-treated patients. These data suggest that hypoestrogenism is associated with decreases in circulating GH and IGF-I.
authors.affiliation: Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
authors.forename: A J
authors.initials: AJ
authors.lastname: Friedman
authors.forename: M S
authors.initials: MS
authors.lastname: Rein
authors.forename: M R
authors.initials: MR
authors.lastname: Pandian
authors.forename: R L
authors.initials: RL
authors.lastname: Barbieri
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004958:Estradiol / Q000097:blood; D005215:Fasting; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013006:Growth Hormone / Q000097:blood*; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007335:Insulin-Like Growth Factor II / Q000378:metabolism*; D007889:Leiomyoma / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D016729:Leuprolide; D010919:Placebos; D013002:Somatomedins / Q000378:metabolism*; D014594:Uterine Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D014599:Uterus / Q000187:drug effects / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D006728:Hormones; D010919:Placebos; D013002:Somatomedins; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D013006:Growth Hormone; D016729:Leuprolide